Kelly G Gwathmey1, Reza Sadjadi1, William B Horton1, Mark R Conaway1, Carolina Barnett-Tapia1, Vera Bril1, James W Russell1, Aziz Shaibani1, Michelle L Mauermann1, Michael K Hehir1, Noah Kolb1, Jeffrey Guptill1, Lisa Hobson-Webb1, Karissa Gable1, Shruti Raja1, Nicholas Silvestri1, Gil I Wolfe1, A Gordon Smith1, Rabia Malik1, Rebecca Traub1, Amruta Joshi1, Matthew P Elliott1, Sarah Jones1, Ted M Burns2. 1. From the Departments of Neurology (K.G.G., A.J., M.P.E., S.J., T.M.B.), Internal Medicine (W.B.H.), and Public Health Sciences (M.R.C.), University of Virginia, Charlottesville; Massachusetts General Hospital/Harvard Medical School (R.S.), Boston, MA; Division of Neurology (C.B.-T., V.B.), Department of Medicine, The Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University of Toronto and University Health Network, Toronto, Canada; Department of Neurology (J.W.R.), University of Maryland, Baltimore; Department of Neurology (A.S.), Baylor St. Luke's Medical Center, Houston, TX; Department of Neurology (M.L.M.), Mayo Clinic, Rochester, MN; Department of Neurology (M.K.H., N.K.), University of Vermont, Burlington; Department of Neurology (J.G., L.H.-W., K.G., S.R.), Duke University Medical Center, Durham, NC; Department of Neurology (N.S., G.I.W.), University at Buffalo, SUNY, Buffalo, NY; Department of Neurology (A.G.S.), Virginia Commonwealth University, Richmond; Department of Neurology (R.M.), Rush University Medical Center, Chicago, IL; and Department of Neurology (R.T.), University of North Carolina, Chapel Hill. 2. From the Departments of Neurology (K.G.G., A.J., M.P.E., S.J., T.M.B.), Internal Medicine (W.B.H.), and Public Health Sciences (M.R.C.), University of Virginia, Charlottesville; Massachusetts General Hospital/Harvard Medical School (R.S.), Boston, MA; Division of Neurology (C.B.-T., V.B.), Department of Medicine, The Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University of Toronto and University Health Network, Toronto, Canada; Department of Neurology (J.W.R.), University of Maryland, Baltimore; Department of Neurology (A.S.), Baylor St. Luke's Medical Center, Houston, TX; Department of Neurology (M.L.M.), Mayo Clinic, Rochester, MN; Department of Neurology (M.K.H., N.K.), University of Vermont, Burlington; Department of Neurology (J.G., L.H.-W., K.G., S.R.), Duke University Medical Center, Durham, NC; Department of Neurology (N.S., G.I.W.), University at Buffalo, SUNY, Buffalo, NY; Department of Neurology (A.G.S.), Virginia Commonwealth University, Richmond; Department of Neurology (R.M.), Rush University Medical Center, Chicago, IL; and Department of Neurology (R.T.), University of North Carolina, Chapel Hill. tmb8r@virginia.edu.
Abstract
OBJECTIVE: We studied the performance of a 15-item, health-related quality-of-life polyneuropathy scale in the clinic setting in patients with diabetic distal sensorimotor polyneuropathy (DSPN). METHODS: Patients with DSPN from 11 academic sites completed a total of 231 Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) scales during their clinic visits. Conventional and modern psychometric analyses were performed on the completed forms. RESULTS: Conventional and modern analyses generally indicated excellent psychometric properties of the CAPPRI in patients with DSPN. For example, the CAPPRI demonstrated unidimensionality and performed like an interval-level scale. CONCLUSION: Attributes of the CAPPRI for DSPN include ease of use and interpretation; unidimensionality, allowing scores to be summed; adequate coverage of disease severity; and the scale's ability to address relevant life domains. Furthermore, the CAPPRI is free and in the public domain. The CAPPRI may assist the clinician and patient with DSPN in estimating disease-specific quality of life, especially in terms of pain, sleep, psychological well-being, and everyday function. The CAPPRI may be most useful in the everyday clinical setting but merits further study in this setting, as well as the clinical trial setting.
OBJECTIVE: We studied the performance of a 15-item, health-related quality-of-life polyneuropathy scale in the clinic setting in patients with diabetic distal sensorimotor polyneuropathy (DSPN). METHODS:Patients with DSPN from 11 academic sites completed a total of 231 Chronic Acquired PolyneuropathyPatient-Reported Index (CAPPRI) scales during their clinic visits. Conventional and modern psychometric analyses were performed on the completed forms. RESULTS: Conventional and modern analyses generally indicated excellent psychometric properties of the CAPPRI in patients with DSPN. For example, the CAPPRI demonstrated unidimensionality and performed like an interval-level scale. CONCLUSION: Attributes of the CAPPRI for DSPN include ease of use and interpretation; unidimensionality, allowing scores to be summed; adequate coverage of disease severity; and the scale's ability to address relevant life domains. Furthermore, the CAPPRI is free and in the public domain. The CAPPRI may assist the clinician and patient with DSPN in estimating disease-specific quality of life, especially in terms of pain, sleep, psychological well-being, and everyday function. The CAPPRI may be most useful in the everyday clinical setting but merits further study in this setting, as well as the clinical trial setting.
Authors: Kelly G Gwathmey; Mark R Conaway; Reza Sadjadi; Amruta Joshi; Carolina Barnett; Vera Bril; Eduardo Ng; William David; Karissa Gable; Jeffrey T Guptill; Lisa D Hobson-Webb; Jennifer Dineen; Michael Hehir; Thomas H Brannagan; Esther Byun; Margaret Adler; Ted M Burns Journal: Muscle Nerve Date: 2015-12-29 Impact factor: 3.217
Authors: V Bril; J England; G M Franklin; M Backonja; J Cohen; D Del Toro; E Feldman; D J Iverson; B Perkins; J W Russell; D Zochodne Journal: Neurology Date: 2011-04-11 Impact factor: 9.910
Authors: Rachel E Sherman; Steven A Anderson; Gerald J Dal Pan; Gerry W Gray; Thomas Gross; Nina L Hunter; Lisa LaVange; Danica Marinac-Dabic; Peter W Marks; Melissa A Robb; Jeffrey Shuren; Robert Temple; Janet Woodcock; Lilly Q Yue; Robert M Califf Journal: N Engl J Med Date: 2016-12-08 Impact factor: 91.245
Authors: Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini Journal: J Clin Endocrinol Metab Date: 2017-12-01 Impact factor: 5.958
Authors: Lindsay A Zilliox; Sandra K Ruby; Sujal Singh; Min Zhan; James W Russell Journal: J Diabetes Complications Date: 2015-02-03 Impact factor: 2.852
Authors: Peter J Dyck; James W Albers; Henning Andersen; Joseph C Arezzo; Geert-Jan Biessels; Vera Bril; Eva L Feldman; William J Litchy; Peter C O'Brien; James W Russell Journal: Diabetes Metab Res Rev Date: 2011-10 Impact factor: 4.876
Authors: Rodica Pop-Busui; Andrew J M Boulton; Eva L Feldman; Vera Bril; Roy Freeman; Rayaz A Malik; Jay M Sosenko; Dan Ziegler Journal: Diabetes Care Date: 2017-01 Impact factor: 19.112
Authors: Derek LeRoith; Geert Jan Biessels; Susan S Braithwaite; Felipe F Casanueva; Boris Draznin; Jeffrey B Halter; Irl B Hirsch; Marie E McDonnell; Mark E Molitch; M Hassan Murad; Alan J Sinclair Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958